. "Argal\u00E1csov\u00E1, So\u0148a" . . "3"^^ . . . "4" . "Farmakogenomick\u00E1 predikce \u00FA\u010Dinnosti tamoxifenu v l\u00E9\u010Db\u011B hormon\u00E1ln\u011B dependentn\u00EDch postmenopauz\u00E1ln\u00EDch \u017Een s karcinomem prsu na z\u00E1klad\u011B korelace aktivity CYP2D6 a rozboru genotypu MDR-1 genu pro P-glykoprotein" . "RIV/00064165:_____/10:7463!RIV13-MZ0-00064165" . "Po\u010D\u00E1te\u010Dn\u00ED stadia karcinomu prsu jsou p\u0159i dob\u0159e veden\u00E9 terapii v dne\u0161n\u00ED dob\u011B ji\u017E chronicky l\u00E9\u010Diteln\u00FDm onemocn\u011Bn\u00EDm. Hormon\u00E1ln\u00ED terapie je jednou ze z\u00E1kladn\u00EDch l\u00E9\u010Debn\u00FDch modalit hormon\u00E1ln\u011B dependentn\u00EDho karcinomu prsu. V p\u0159edkl\u00E1dan\u00E9m \u010Dl\u00E1nku V\u00E1m nab\u00EDz\u00EDme na\u0161e dosavadn\u00ED v\u00FDsledky vlivu v\u00FD\u0161e uveden\u00FDch faktor\u016F na \u00FA\u010Dinnost tamoxifenu v adjuvantn\u00ED hormon\u00E1ln\u00ED terapii postmenopauz\u00E1ln\u00EDch pacientek s lok\u00E1ln\u00EDm, event. lok\u00E1ln\u011B pokro\u010Dil\u00FDm hormon\u00E1ln\u011B dependentn\u00EDm karcinomem prsu."@cs . . . "P(NS10563), V" . "[5904AC8E192F]" . "Petru\u017Eelka, Lubo\u0161" . . . "Slana\u0159, Ond\u0159ej" . . . . "Pharmacogenomical prediction of the effect of taxifen in the treatment of hormonal-dependent post-menopausal women with breast cancer"@en . "http://www.onkologiecs.cz/pdfs/xon/2010/05/11.pdf" . . "Farmakogenomick\u00E1 predikce \u00FA\u010Dinnosti tamoxifenu v l\u00E9\u010Db\u011B hormon\u00E1ln\u011B dependentn\u00EDch postmenopauz\u00E1ln\u00EDch \u017Een s karcinomem prsu na z\u00E1klad\u011B korelace aktivity CYP2D6 a rozboru genotypu MDR-1 genu pro P-glykoprotein"@cs . "The initial stages of breast cancer are well treatable nowadays, provided the therapy is appropriate. Hormonal therapy is one of the basic therapeutic modalities for the hormone- dependent breast cancer. In this artikle, we offer our preliminary results of several factors influencing the effect of tamoxifen, extended with new, yet unexplored factor \u2013 polymorfism of MDR-1."@en . . "5" . "AmpliChip; tamoxifen; molecular diagnosis; CYP2D6; MDR-1; P-glycoprotein; concomitant medication (comediaction); farmacogenomic"@en . "258776" . "Farmakogenomick\u00E1 predikce \u00FA\u010Dinnosti tamoxifenu v l\u00E9\u010Db\u011B hormon\u00E1ln\u011B dependentn\u00EDch postmenopauz\u00E1ln\u00EDch \u017Een s karcinomem prsu na z\u00E1klad\u011B korelace aktivity CYP2D6 a rozboru genotypu MDR-1 genu pro P-glykoprotein"@cs . . . "4"^^ . "Po\u010D\u00E1te\u010Dn\u00ED stadia karcinomu prsu jsou p\u0159i dob\u0159e veden\u00E9 terapii v dne\u0161n\u00ED dob\u011B ji\u017E chronicky l\u00E9\u010Diteln\u00FDm onemocn\u011Bn\u00EDm. Hormon\u00E1ln\u00ED terapie je jednou ze z\u00E1kladn\u00EDch l\u00E9\u010Debn\u00FDch modalit hormon\u00E1ln\u011B dependentn\u00EDho karcinomu prsu. V p\u0159edkl\u00E1dan\u00E9m \u010Dl\u00E1nku V\u00E1m nab\u00EDz\u00EDme na\u0161e dosavadn\u00ED v\u00FDsledky vlivu v\u00FD\u0161e uveden\u00FDch faktor\u016F na \u00FA\u010Dinnost tamoxifenu v adjuvantn\u00ED hormon\u00E1ln\u00ED terapii postmenopauz\u00E1ln\u00EDch pacientek s lok\u00E1ln\u00EDm, event. lok\u00E1ln\u011B pokro\u010Dil\u00FDm hormon\u00E1ln\u011B dependentn\u00EDm karcinomem prsu." . . . . . . "3"^^ . "RIV/00064165:_____/10:7463" . "Pharmacogenomical prediction of the effect of taxifen in the treatment of hormonal-dependent post-menopausal women with breast cancer"@en . "1802-4475" . . "Onkologie" . . "CZ - \u010Cesk\u00E1 republika" . "Farmakogenomick\u00E1 predikce \u00FA\u010Dinnosti tamoxifenu v l\u00E9\u010Db\u011B hormon\u00E1ln\u011B dependentn\u00EDch postmenopauz\u00E1ln\u00EDch \u017Een s karcinomem prsu na z\u00E1klad\u011B korelace aktivity CYP2D6 a rozboru genotypu MDR-1 genu pro P-glykoprotein" . .